A61K31/695

Oil-based pharmaceutical composition for the treatment of gastrointestinal diseases
09789192 · 2017-10-17 · ·

The present invention relates to a composition for oral use in the treatment of gastrointestinal pathologies comprising silicone antifoaming agents in an oily solvent medium, wherein the concentration of said silicone antifoaming agents is between 0.1% and 80% by weight.

Oil-based pharmaceutical composition for the treatment of gastrointestinal diseases
09789192 · 2017-10-17 · ·

The present invention relates to a composition for oral use in the treatment of gastrointestinal pathologies comprising silicone antifoaming agents in an oily solvent medium, wherein the concentration of said silicone antifoaming agents is between 0.1% and 80% by weight.

Heterocyclic compounds and uses thereof
09822109 · 2017-11-21 · ·

Heterocyclic compounds of formula (I), methods for their preparation, pharmaceutical compositions containing such a compound and their therapeutic uses.

Heterocyclic compounds and uses thereof
09822109 · 2017-11-21 · ·

Heterocyclic compounds of formula (I), methods for their preparation, pharmaceutical compositions containing such a compound and their therapeutic uses.

Kinase inhibitors

There are provided compounds of formula I, (I): ##STR00001## wherein R.sup.1 to R.sup.5, X.sup.1, X.sup.2, Ar, L, E, A, A1, G and G.sup.1 have meanings given in the description, which compounds have anti-inflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

Kinase inhibitors

There are provided compounds of formula I, (I): ##STR00001## wherein R.sup.1 to R.sup.5, X.sup.1, X.sup.2, Ar, L, E, A, A1, G and G.sup.1 have meanings given in the description, which compounds have anti-inflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

DIAMINOHETEROARYL SUBSTITUTED INDAZOLES

Compounds of formula (I) which are inhibitors of Bub 1 kinase, processes for their production and their use as pharmaceuticals.

DIAMINOHETEROARYL SUBSTITUTED INDAZOLES

Compounds of formula (I) which are inhibitors of Bub 1 kinase, processes for their production and their use as pharmaceuticals.

PHOTODYNAMIC THERAPY COMPOSITION
20170281789 · 2017-10-05 ·

A phthalocyanine compound or targeted conjugate thereof having the formula (I).

PHOTODYNAMIC THERAPY COMPOSITION
20170281789 · 2017-10-05 ·

A phthalocyanine compound or targeted conjugate thereof having the formula (I).